Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. announced that two new indications for its products, Toripalimab Injection (TUOYI) and Ongericimab Injection (JUNSHIDA), have been added to China’s National Reimbursement Drug List (NRDL) effective January 2026. This inclusion marks a significant milestone for the company, as all 12 indications of TUOYI are now covered, making it the only anti-PD-1 monoclonal antibody in the NRDL for renal cancer, TNBC, and melanoma. JUNSHIDA’s inclusion is notable as it is the only domestic PCSK9-targeted drug for statin-intolerant patients in the NRDL, enhancing the company’s market positioning and potential stakeholder benefits.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative drugs. The company specializes in therapeutic biological products, including antineoplastic drugs and immune modulators, with a market focus on oncology and cardiovascular diseases.
Average Trading Volume: 5,497,756
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.48B
See more data about 1877 stock on TipRanks’ Stock Analysis page.